Table 3.
Acute care utilization among SLE hydroxychloroquine (HCQ) and immunosuppressive (IS) new users by adherers (MPR≥80%) versus nonadherers (MPR<80%) during follow-up year
| Number of Visits |
Emergency Department Visits |
Hospitalizations | |||
|---|---|---|---|---|---|
| All-cause N (%) |
SLE-related N (%) |
All-cause N (%) |
SLE-related N (%) |
||
| HCQ Adherers N=2048 | 0 | 1188 (58.0) | 1783 (87.1) | 1551 (75.7) | 1674 (81.7) |
| 1 | 399 (19.5) | 177 (8.6) | 284 (13.9) | 227 (11.1) | |
| ≥2 | 461 (22.5) | 88 (4.3) | 213 (10.4) | 147 (7.2) | |
| Mean (SD) | 1.13 (2.71) | 0.21 (0.70) | 0.49 (1.28) | 0.32 (0.92) | |
| HCQ Nonadherers N=7552 | 0 | 3789 (50.1) | 6113 (81.0) | 5378 (71.2) | 5924 (78.4) |
| 1 | 1388 (18.4) | 882 (11.7) | 1143 (15.1) | 952 (12.6) | |
| ≥2 | 2375 (31.5) | 557 (7.4) | 1031 (13.7) | 676 (9.0) | |
| Mean (SD) | 1.70 (3.72) | 0.36 (1.13) | 0.65 (1.61) | 0.42 (1.12) | |
| IS Adherers N=651 | 0 | 367 (56.4) | 551 (84.6) | 471 (72.4) | 514 (79.0) |
| 1 | 120 (18.4) | 58 (8.9) | 97 (14.9) | 88 (13.5) | |
| ≥2 | 164 (25.2) | 42 (6.5) | 83 (12.8) | 49 (7.5) | |
| Mean (SD) | 1.15 (2.06) | 0.25 (0.77) | 0.52 (1.17) | 0.33 (0.77) | |
| IS Nonadherers N=3178 | 0 | 1465 (46.1) | 2465 (77.6) | 2114 (66.5) | 2400 (75.5) |
| 1 | 603 (19.0) | 423 (13.3) | 512 (16.1) | 418 (13.2) | |
| ≥2 | 1110 (34.9) | 290 (9.1) | 552 (17.4) | 360 (11.3) | |
| Mean (SD) | 1.94 (3.89) | 0.46 (1.36) | 0.84 (1.88) | 0.53 (1.36) | |
All p-values <0.05 from Chi-square tests comparing adherers to nonadherers for all-cause and SLE-related emergency department visits and hospitalizations